Treatment of bronchial carcinoma in the elderly;Traitement du cancer bronchique du sujet âgé

Revue des Maladies Respiratoires

Volumn 19, Issue 5 I, 2002, Pages 616-626

  Diab, S ^a   Geriniere, L ^a   Carrie, C ^a   Souquet, Pierre Jean ^a  

^a CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

Chemotherapy; Elderly; Lung cancer; Radiotherapy; Surgery

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE; VINCRISTINE;

AGED; AGING; BLOOD TOXICITY; BONE MARROW TOXICITY; DRUG HYPERSENSITIVITY; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; HEART FAILURE; HEMOPTYSIS; HUMAN; INOPERABLE CANCER; LEUKOPENIA; LIVER TOXICITY; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; NEPHROTOXICITY; NEUROTOXICITY; RESPIRATORY FAILURE; REVIEW; THROMBOCYTOPENIA; TREATMENT INDICATION;

AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; GERIATRICS; HUMANS; LUNG NEOPLASMS; PALLIATIVE CARE; QUALITY OF LIFE; RADIOTHERAPY;

EID: 17944395596     PISSN: 07618425     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Samet J, Hunt WC, Key C, Humble CG, Goodwin JS: Choice of cancer therapy varies with age of patient. JAMA 1986;255:3385-90.
2. Ganz P: Interaction between the physician and the older patient. Cancer 1997;80:1323-5.
3. Berkman B, Rohan B, Sampson S: Myths and biases related to cancer in the elderly. Cancer 1994;74:2004-8.
4. Bernet F, Brodbek R, Guenin M-O, Schupfer G, Habicht JM, Stulz PM, Carrel TP: Age does not influence early and late tumor related outcome for bronchogenic carcinoma. Ann Thor Surg 2000;69:913-8.
5. Thyss A, Saudes L, Otto J, Creisson A, Gaspard MH, Dassonville O, Schneider M: Renal Tolerance of Cisplatin in Patients more than 80 years old. J Clin Oncol 1994;12:2121-5.
6. Fry W, Philips JL, Menck HR: Ten-year survey of lung cancer treatment and survival in hospitals in the United States. Cancer 1999;86:1867-76.
7. Pailler M Ch: Cancer du poumon chez le sujet âgé. La Lettre du Cancérologue 2000;9:23-6.
8. Hutchins LF, Unger JM, Crowley JJ, Coltman CA, Albain KS: Under representation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999;341:2061-7.
9. Sherman S, Guidot CE: The feasibility of thoracotomy for lung cancer in the elderly. JAMA 1987;258:927-30.
10. Regnard JF, Calanducci F, Denet C: Resections pulmonaires pour cancer chez l'octogénaire. Rev Mal Respir 1998;15:649-55.
11. Riquet M, Medioni J, Manach D, Dujon A, Souilamas R, Le Pimpec, Barthes F, Hubsch JP: Cancer pulmonaire non à petites cellules: Particularités chirurgicales en fonction de l'âge. Rev Mal Respir 2001;18:173-84.
12. Suzuki K, Nagai K, Yoshida J, Nishimura M, Takahashi K, Yokose T, Nischiwaki Y: Conventional Clinicopathologic prognostic factors in surgically resected non small cell lung carcinoma. Cancer 1999;86:1976-84.
13. Jaklitsch MT, Bueno R, Swanson SJ, Mentzer S, Lukanich JM, Sugarbaker DJ: New surgical options for elderly lung cancer patients. Chest 1999;116:480S-485S.
14. Souquet P-J, Chauvin F, Boissel JP, Cellerino R, Cormier Y, Ganz PA, Kaasa S, Pater JL, Quoix E, Rapp E, Bernard JP: Polychemotherapy in advanced non small cell lung cancer: A meta-analysis. Lancet 1993;342:19-21.
15. Non Small Cell Lung Cancer Collaborative Group: Chemotherapy in non small cell lung cancer: A meta analysis using updated individual patient data from 52 randomised clinical trials. Br Med J 1995;311:899-909.
16. Souquet PJ, Lombard-Bohas C, Freyer G, Bombaron P, Geriniere L, Bernard JP: Chimiotherapie des cancers bronchiques des sujets agés. Rev Mal Respir 1996;13:327-33.
17. Balducci L, Parker M, Sexton W, Trantanond P: Pharmacology of antineoplastic agents in the elderly patient. Semin Oncol 1989;16:76-84.
18. Hrusheshki W, Shimp W, Kennedy BJ: Lack of age dependant cisplatin nephrotoxicity. Am J Med 1984;76:579-89.
19. Chatta M: Aging and neutrophil response to r met Hu G-CSF. Proc of ASCO 1993;12:108.
20. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltschaw E: Carboplatin dosage: Prospective evaluation of simple formula based on renal function. J Clin Oncol 1989;7:169-80.
21. Freyer G, Maire P, Ardiet C, Tranchand B, Droz JP: Chimiothdrapies cytotoxiques et sujets agés: Constats et perspectives. Bull Cancer 1995;82:531-40.
22. Nguyen B, Sandler A, Denhan C: The safety and efficacy of gemcitabine plus cisplatine in the elderly chemonaive NSCLC patients as compared to those with age < 70 years. Proc ASCO 1999;18:471A-1818.
23. Lippe P, Silva RR, Monterubbianesi MC, Giulodori L, Maru D, Cancellari MA, Santo A, Pasini F, Cetto GL, Rossi D, Porfiri E, Cascinu S, Cellerino R: Advanced non small cell lung cancer in the elderly: Symptoms-relief after weekly gemcitabine and cisplatine. Proc ASCO 1999;18:514a-1984.
24. Kubota K, Furuse K, Kahawara M, Kodama N, Ogawara M, Takada M, Masuda N, Negoro S, Matsui K, Takifuji N, Kudoh S, Kusunoki Y, Fukuoka M: Cisplatin-based combination chemotherapy for elderly patients with non-small-cell lung cancer. Cancer Chemother Pharmacol 1997;40:469-74.
25. Langer C, Manola J, Bernardo P, Bonomi P, Kugler A, Johnson D: Advanced Age alone does not compromise outcome in fit non-small lung cancer (NSCLC) Patients receiving platinum (DDP) -based therapy (TX): Implications of ECOG 5592. Proc ASCO 2000;19:1912.
26. Gridelli C, Perrone F, Gallo C, DA Marinis F, Ianiello G, Cigolari S, Cariello S, Di Costenza F, D'Aprile M, Rossi A, Migliorino R, Bartolucci R, Bianco AR, Pergola M, Monfardini S: Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small-cell lung cancer: A two stage phase II study. Eur J Cancer 1997;33:392-9.
27. Manente P, Colleoni M, Gaion F, Sgarbossa G, Nelli P: Vinorelbine in Elderly patients with advanced non-small cell lung cancer. Ann Oncol 1994;5:P294.
28. Buccheri G, Ferrigno D: Vinorelbine in elderly patients with inoperable non small cell lung cancer carcinoma. Cancer 2000;88:2677-85.
29. Gridelli C, Perrone F, Gallo C and the Elvis group: Effects of vinorelbine on quality of life and survival of elderly patients with advanced non small cell lung cancer. J Natl Cancer Inst 1999;91:66-72.
30. Depierre A, Jassem J, Ramlau R, Karnicka-Mlodkowska H, Krawczyk K, Krzakowski M, Zlatoukal P: Feasibility and safety of Navelbine oral with an intrapatient dose escalation versus Navelbine intravenous in advanced/metastic non small cell lung cancer. Lung Cancer 2000;29:29-31.
31. Ardizzoni A, Martin C, Gaafar R, Bucholdz E, Debruyne C, Damen S, Rosso R: Gemcitabine toxicity and efficacy unaffected by age in advanced non-small cell lung cancer. Ann Oncol 1994;5:P295.
32. Shepherd FA, Abratt R, Anderson H, Gatzmeier U, Anglin G, Iglesias J: Gemcitabine in the treatment of elderly patients with advanced non small cell lung cancer. Semin Oncol 1997;24:50-5.
33. Burkes RL, Wilson J, Shepherd FA, Spadafora S, Iglesias J: Single agent gemcitabine for elderly patients with non small cell lung cancer: A phase II study. Lung Cancer 2000;29:32.
34. McKay CE, Hainsworth JD, Burris HA, Litchi S, Morissey LH, Barton JA, Greco FA: Weekly Docetaxel in the treatment of elderly patients with advanced non-small lung Cancer (NSCLC): A Minnie Pearl Cancer Research network phase II trial. Proc ASCO 2000;19:1964.
35. Feliu J, Gomez L, Madronal C, Espinosa E, Espinosa J, Garcia Giron C, Martinez B, Castro J, Dela Gandara I, Baron MG: Gemcitabine plus Vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatine. Cancer 1999;86:1463-9.
36. Lilembaum R, Cano R, Scwartz M, Siegel L, Lutzky J, Lewis M, Krill E, Barreras L, Davila EI: Gemcitabine and Vinorelbine in advanced non-small-cell lung carcinoma. Cancer 2000;88:557-62.
37. Frasci G, Lorusso V, Panza N, Comella P, Nicolella G, Bianco A, De Cataldis G, Belli M, Ianelli N, Massida B Mascia E, Comella G, De Lena M: Gemcitabine+ vinorelbine yields better survival than vinorelbine alone in elderly non small cell lung cancer patients. Final analysis of a southern Italy Cooperative Oncology Group phase III trial. Lung Cancer 2000;29:50.
38. Gridelli C, Perrone F, Cigolari S, Manzione L, Piantodesa F, Barbesa S, De Marinis F: The MILES phase III trial Gemcitabine + Vinorelbine vs Vinorelbine and vs Gemcitabine in elderly advanced NSCLC patients Proc ASCO 2001; Abstr1230.
39. Edelman MJ, Gandara DR, Lau D, Lara P, Lauder I: Sequential chemotherapy with carboplatine and gemcitabine followed by paclitaxel in poor performance status and elderly patients with non small cell lung cancer. Lung Cancer 2000;29:16.
40. Tyldesley S, Zhang-Salomon S, Groome PA, Zhou S, Schulze K, Paszat LF, Mackillop WJ: Association between age and the utilisation of radiotherapy in Ontario. Int J Radiation Oncology Biol Phys 2000;47:469-80.
41. Lonardi F, Coeli M, Pavanoto G, Adami F, Gioga G, Campostini F: Radiotherapy for non small cell lung cancer in patients aged 75 and over: Safety, effectiveness and possible impact on survival. Lung Cancer 2000;28:43-50.
42. Pignon T, Gregor A, Koning CS, Roussel A, Van Glabekke M, Scalliet P: Age has no impact on acute and late toxicity of curative thoracic radiotherapy. Radiother Oncol 1998;46:239-48.
43. Zachariah B, Balducci L, Venkattaramanabalaji GV, Casey L, Greenberg H, Delregato JA: Radiotherapy for cancer patients aged 80 and older: A study of effectiveness and side effects. Int J Radiation Oncology Biol Phys 1997;39:1125-9.
44. Geara F, Komaki R, Tucker S, Travis EL, Cox JD: Factors influencing the development of lung fibrosis after chemoradiation for small cell carcinoma of the lung: Evidence for inherent interindividual variation. Int J Radiation Oncology Biol Phys 1998;41:279-86.
45. Maguire PD, Sibley GS, Zhou S-M, Jamieson TA, Light KL, Antoine PA, Herndon JE II, Anscher MS, Marks LB: Clinical and dosimetric predictors of radiation-induced esophagal toxicity. Int J Radiation Oncology Biol Phys 1999;45:97-103.
46. Jeremic B, Shibamato Y, Milicic B, Milisavljevic S, Nikolic N, Dagovic A, Aleksandrovic J: A phase II study of concurrent accelerated hyperfracitonated radiotherapy and carboplatin/oral etoposide for elderly patients with stage III non small cell lung cancer. Int J Radiation Oncology Biol Phys 1999;44:343-8.
47. Le Pechoux C, Arriagada R: La radiotherapie dans un abord pluridisciplinaire. Rev Mal Respir 1998;15:407-19.
48. Noordijk EM, Clement EP, Hermans J: Radiotherapy as an alternative to surgery in elderly patients with resectable lung cancer. Radiother Oncol 1988;13:83-9.
49. Krol AG, Aussems P, Noordijk EM: Local irradiation alone for peripheral stage I lung cancer: Could we omit the elective regional nodal irradiation? Int J Radiat Oncol Biol Phys 1997;39:537-44.
50. Sunyach M-P, Falchero L, Pommier P, Perol, M, Arpin D, Vincent M, Boutry D, Rebattu P, Ginestet C, Martellafay I, Perol D, Carrie C: Prospective evaluation of early lung toxicity following three-dimensional conformal radiation therapy in non small cell lung cancer: Preleminary results. Int J Radiat Oncol Biol Phys 2000;48:459-63.
51. Byrne A, Carney DN: Small cell lung cancer in the elderly. Semin Oncol 1994;21:43-8.
52. Arriagada R, Le Chevallier T, Pignon JP, Riviere A, Monnet I, Chomy P, Tuchais C, Tarayre M, Ruffie P: Initial chemotherapeutic doses and survival in patients with limited small cell lung cancer. N Engl J Med 1993;329:1848-52.
53. Thatcher N, Lee SM, Woll PJ, Middletown M, Anderson H, Burt P, Stout R: Dose intensity in small cell lung cancer. Semin Oncol 1998;25:434-5.
54. Siu LL, Shepherd FA, Murray N, Feld R, Pater J, Zee B: Influence of Age on the treatment of limited stage small-cell lung cancer. J Clin Oncol 1996;14:821-8.
55. Yuen A, Zou G, Turrisi A, Sause W, Komaki R, Wagner H, Aisner SC, Livingston RB, Blum R, Johnson DH: Similar outcome of elderly patients in Intergroup trial 0096: Cisplatine, etoposide, and thoracic radiotherapy administred once or twiced daily in limited stage small cell lung cancer. Cancer 2000;89:1953-60.
56. Murray N, Grafton C, Shah A, Gelmon K, Kostashuk E, Brown E, Coppin C, Coldman A, Page R: Abbreviated treatment for elderly, infirm, or noncompliant patients with limited-stage small-cell lung cancer. J Clin Oncol 1998;16:3323-8.
57. Westeel V, Murray N, Gelmon K, Shah A, Sheehan F, Mckenzie M, Wong F, Morris J, Grafton C, Tsang V, Goddard K, Murphy K, Parsons C, Amy R, Page R: New combination of the old drugs for elderly patients with small-cell lung cancer: A phase II study of the PAVE regimen. J Clin Oncol 1998;16:1940-7.
58. Freyer G, Ligneau B, Tranchand B, Ardiet C, Souquet PJ, Court-Fortune I, Riou R, Rebattu P, Morignat E, Boissel JP, Trillet-Lenoir V, Girard P: The prognostic value of etoposide area under the curve (AUC) at first chemotherapy cycle in small cell lung cancer patients. Lung Cancer 2001;31:247-56.
59. Bunn P: Clinical experiences with carboplatine in lung cancer. Semin Oncol 1992;19:368-71.
60. Okamoto H, Watanabe K, Nishiwaki Y, Mori K, Kurita Y, Hayashi I, Masutani M, Nakata K, Tsuchiya S, Isobe H, Saijo N: Phase II study of area under the plasma-concentration-versus time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small cell lung cancer. J Clin Oncol 1999;17:3540-5.
61. Satoh H., Ishikawa H., Funayama Y, Yamashita Y, Kamma H, Ohtsuka M, Sekizawa: Management of small cell lung cancer in elderly. Anticancer Research 1999;19:4507-10.
62. Castelnau O, Perol M, Vergnenegre A, Blanchon F, Arnaud A, Taytard A, Guerin JC, Bonnaud F, Kleisbauer JP: Association carboplatine-VP 16 per os dans les cancers bronchiques non à petites cellules du sujet âgé (GFPC). Bull Cancer 1995;82:63-6.
63. Larivé, S, Bombaron P, Riou R, Fournel P, Perol M, Lena H, Dussopt C, Philip-Joet F, Touraine F, Lecaer H, Souquet PJ: Carboplatine-etoposide oral dans le cancer bronchique à petites cellules du sujet agé: Une étude de phase II [abstract]. Rev Mal Respir 1999;16:1S68
64. Auperin A, Arriagada R, Pignon J-P, Le Pechoux C, Gregor A, Stephens RJ, Kristjansen PE, Johnson BE, Ueoka H, Wagner H, Aisner J: Prophylactic cranial irradiation for patients with small cell lung cancer in complete remission. N Engl J Med 1999;341:476-84.
65. Warde P, Payne D: Does thoracic irradiation improve survival and local control in limited stage small cell carcinoma of the lung? A meta-analysis. J Clin Oncol 1992;10:890-5.
66. Souhami RL, Spiro S, Rudd RM, Ruiz De Elvira MC, James LE, Gower NH, Lamont A, Harper PG: Five days oral etoposide treatment for advanced small cell lung cancer: Randomized comparison with IV chemotherapy. J Natl Cancer Inst 1997;89:557-60.